Pfizer Commences New Biotech Facility In Sweden

Pfizer has opened a new biotech facility in Sweden, which will be used to make products including a branded version of human growth hormone.

The company said that it has invested $214.8m in the plant at Strangnas. The 6,000 square meters facility is likely to manufacture Pfizer’s human growth hormone, or Genotropin, along with the drug Somavert for acromegaly, and drugs based on E. coli and yeast.

Genotropin, a growth hormone treatment, has been proven to be safe and effective. Genotropin has been approved by the FDA to treat growth failure in: children with growth hormone deficiency (GHD), children with Prader-Willi syndrome (PWS), children born small for gestational age (SGA), girls with Turner syndrome (TS), children with Idiopathic Short Stature (ISS), and adults with growth hormone deficiency (aGHD).